比较HeartMate 3与心脏移植作为晚期心衰主要治疗的3年生存率与再入院情况
本中心回顾性分析381例接受HeartMate 3左心室辅助装置或 listed for 心脏移植的成人患者,经倾向评分匹配后每组104例;匹配后3年生存率HM3组83.7% vs OHT组87.0%(P=.91;RR 1.00;95%CI 0.45-2.20)无统计学差异,但HM3组3年平均再入院次数更高(3.89 vs 2.05;P<.001)。作者认为HM3可能提供与OHT相当的3年生存率但再入院更多。
要点
- 匹配后HM3与OHT的3年生存率无统计学差异(83.7% vs 87.0%;P=.91)。
- HM3组3年平均再入院次数高于OHT组(3.89 vs 2.05;P<.001)。
- 未匹配队列中18-49岁患者两组生存率相当(96.9% vs 95.9%)。
核心结论
- 此项探索性分析提示,对于相似患者,HM3作为心衰主要治疗可能提供与OHT相当的3年生存率,但可能导致更多再入院。
研究设计与样本
- 本中心回顾性分析2014年1月至2021年3月期间接受HM3左心室辅助装置或 listed for 心脏移植的381例成人患者。
- 排除既往有LVAD的OHT受者,HM3患者在移植时删失,采用倾向评分匹配以减少混杂变量。
- 研究人群包括185例HM3患者(49%)和196例OHT患者(51%),倾向评分匹配后每组104例。
主要发现
- 倾向评分匹配后,3年生存率HM3组83.7% vs OHT组87.0%(P=.91;RR 1.00;95%CI 0.45-2.20),无统计学差异。
- 未匹配队列中,18-49岁患者HM3与OHT生存率相当(96.9% vs 95.9%;N=91;P=1.00;RR 0.92;95%CI 0.09-9.78)。
- 未匹配队列中,50岁及以上患者HM3生存率略低(75.0% vs 83.9%;N=290;P=.60;RR 1.51;95%CI 0.85-2.68)。
- HM3组3年平均再入院次数高于OHT组(3.89 vs 2.05;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare 3-year survival and readmissions of patients who received the HeartMate 3 (HM3) left ventricular assist device (LVAD) or underwent orthotopic heart transplantation (OHT) as primary treatment for advanced heart failure. METHODS: We retrospectively analyzed 381 adult patients who received an HM3 LVAD or were listed for OHT between January 2014 and March 2021 at our center. To minimize crossover bias, OHT recipients with a prior LVAD were excluded, and HM3 patients were censored at the time of transplant. Cohorts were propensity score-matched to reduce confounding variables. The primary outcome was 3-year survival, and the secondary outcome was mean cumulative all-cause unplanned readmission. RESULTS: The study population comprised 185 HM3 patients (49%) and 196 OHT patients (51%), with 104 propensity score-matched patients in each group. After propensity score matching, there was no statistical difference in 3-year survival (83.7% for HM3 vs 87.0% for OHT; P = .91; relative risk [RR], 1.00; 95% confidence interval [CI], 0.45-2.20). In the unmatched cohorts, patients age 18 to 49 years had comparable survival with HM3 and OHT (96.9% vs 95.9%; N = 91; P = 1.00; RR, 0.92; 95% CI, 0.09-9.78). Patients age 50+ years had slightly inferior survival with HM3 (75.0% vs 83.9%; N = 290; P = .60; RR, 1.51; 95% CI, 0.85-2.68). The mean number of readmissions at 3 years was higher in the HM3 group (3.89 vs 2.05; P < .001). CONCLUSIONS: This exploratory analysis suggests that for similar patients, HM3 may provide comparable 3-year survival to OHT as a primary treatment for heart failure but may result in more readmissions.
引用
- Kirschner M, Topkara VK, Sun J, et al. Comparing 3-year survival and readmissions between HeartMate 3 and heart transplant as primary treatment for advanced heart failure. J Thorac Cardiovasc Surg. 2023. PMID: 38154500. doi:10.1016/j.jtcvs.2023.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。